APLS insider filings: Sinclair dispositions include 158,393 shares listed
Rhea-AI Filing Summary
Apellis Pharmaceuticals director Dunlop A. Sinclair reported multiple dispositions of Apellis common stock on 09/30/2025. The filing shows a sale of 31,092 shares at a weighted average price of $22.58 (individual sale prices ranged from $22.23 to $22.74). The filer states these sales were executed under a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on June 20, 2025. The report lists an additional 3,837-share distribution at no consideration and includes a separate disposition line showing 158,393 shares disposed, without price detail in the table. Sinclair is identified as a director and as having indirect ownership through Epidarex, which holds voting and dispositive power over the shares.
Positive
- Transaction executed under a Rule 10b5-1 trading plan, indicating preplanned dispositions (adopted June 20, 2025).
- Filer disclosed weighted-average sale price and price range ($22.58; $22.23–$22.74), improving transparency.
Negative
- Director reported significant dispositions including a 31,092-share sale and a listed 158,393-share disposition, reducing indirect holdings.
- Large change in reported beneficial ownership (beneficial shares reported following transactions fall to 30,142 in one line), which may concern investors monitoring insider selling.
Insights
Director sales executed under a Rule 10b5-1 plan; disclosure is routine but material.
The filing explicitly states the sales on 09/30/2025 were effected under a Rule 10b5-1 plan adopted by Epidarex Capital I LP on June 20, 2025, which indicates the transactions were preplanned rather than opportunistic. That reduces the likelihood that these sales reflect contemporaneous insider views, but the filing still notifies investors that a director’s indirect holdings changed meaningfully on that date.
Insider dispositions total at least tens of thousands of shares; market impact depends on float size.
The report documents a weighted-average-priced sale of 31,092 shares at $22.58 and a separate 158,393-share disposition line plus a 3,837-share distribution. These are concrete changes in beneficial ownership and could be relevant to liquidity and near-term supply, though the filing does not provide context on total outstanding shares or percent ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 31,092 | $22.58 | $702K |
| Other | Common Stock | 3,837 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP ("Epidarex") on June 20, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.23 to $22.74, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. The securities are held by Epidarex, and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein. Represents a stock distribution from Epidarex to a Limited Partner and General Partner of Epidarex, for no consideration.
